Following Moderna's breakthrough cancer vaccine trial, Chinese companies including Jiangsu Hengrui Pharmaceuticals and Li Ka-shing-backed CK Life Sciences are pushing forward with similar programmes. These companies have seen their stock prices surge, eyeing a large potential market given that nearly 2.6 million people die from cancer in China alone each year.